199 results about "Luteinizing hormone" patented technology

Methods, devices and test kits for monitoring the ovulation cycle, involve testing the body fluid, e.g. urinary, concentration of one or more analytes. Preferably estrone-3-glucuronide and luteinizing hormone are both measured, and a reference concentration for E3G is established at about day 6 of the current cycle. Preferably, disposable testing devices are used, in conjunction with a relatively permanent electronic reader / monitor. The number of "daily" tests required per month can be minimized.

A complex is provided for the treatment of neurogenic conditions having the formula: where R1 is M is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium (II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium (II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium (II):transporter ligand.

A compound is provided that has the formula NH2CH2CH2CH2C(O)N—R   (I) where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

There are provided a fused pyrimidine compound having antagonistic activity against luteinizing hormone releasing hormone, and a medicine containing the compound. A luteinizing hormone releasing hormone antagonist containing a compound represented by the formula: wherein R1a is a hydrocarbon group which may be substituted or a hydrogen atom, ring Aa is a 6-membered aromatic ring which may be further substituted, ring Ba is a homocyclic or heterocyclic ring which may be further substituted, Wa is an oxygen atom or a sulfur atom, Xa1 and Xa2, which may be identical or different, are each a hydrogen atom, a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted, or Xa1 and Xa2 together may form an oxygen atom, a sulfur atom or NR3a (wherein R3a is a hydrocarbon group which may be substituted or a hydrogen atom), and Ya is C1-6 alkylene which may be substituted or a bond, or a salt or prodrug thereof.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

The invention discloses a method and application for inducing human umbilical cord mesenchyme stem cells to be differentiated into testicular interstitial cells. The method comprises the following step of culturing human umbilical cord mesenchyme stem cells of patients suffering from adenovirus and carrying mice steroidogenic factor-1 genes in a DMEM-F12 culture solution containing 0.3-3ng / ml of luteinizing hormone, 200-800mu M of dibutyryl cyclic adenosine monophosphate, 5*10<-6>-5*10<-4>M of all-trans retinoic acid (ATRA), 10mU / ml of human chorionic gonadotropin and 2.4uM of adrenocorticotrophic hormone for a week. Induced by the method in the invention, the human umbilical cord mesenchyme stem cells can be differentiated into testicular interstitial cells in vitro and provides important sources of cells for treating testosterone shortage by the cell replacing method or the genetic method.

A compound is provided that has the formula NH2CH2CH2CHR1C(O)N—R  (I) where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

The present invention is related to a diagnostic test kit for detecting luteinizing hormone (LH) in a biological sample at a concentration relative to a threshold concentration of LH. The device can include a release medium formed of a first material and including a labeled conjugate with a detectable label and a first binding member reactive with a first epitope of LH and a capture medium formed of a second, different material, in fluid communication with the release medium. The capture medium includes a result site having immobilized thereon a capture component capable of directly or indirectly binding LH that is bound to the labeled conjugate. The device is calibrated such that color development at the result site occurs only when the LH concentration of the liquid sample is greater than the threshold concentration.

A complex is provided for the treatment of neurogenic conditions having the formula:where R1 isM is a metal ion Ca(II), Mg(II), Cu(II) or Ni(II); n is an integer 1 or 2; R is BBB peptide, transferrin, membrane transporter peptide, TAT peptide, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, L-lactate, L-leucine, L-tryptophan, and L-glutamate; and R is coupled to M through a carboxylate moiety. Magnesium(II) represents the preferred metal ion as magnesium is known to have neuroprotective effects. The metal ion is in part chelated by a non-steroidal anti-inflammatory drug that does not inhibit platelet activity and includes salicylate and ibuprofenate. The complex also includes a ligand operative in transport across the blood brain barrier. A process for making an inventive complex includes the stoichiometric addition of ligands containing carboxylate groups to a solution of the metal ion. In instances where the metal ion is magnesium(II), a stoichiometric ratio of 1:1:1 is found between the non-steroidal anti-inflammatory ligand:magnesium(II):transporter ligand.

The present invention relates to a composite microsphere system comprising poly(D,L-lactide-co-glycolide) (PLGA), poly(acryloyl hydroxyethyl starch) (AcHES), and a pharmaceutically effective amount of a biologically active compound. The active compound may be, for example, an insulin, an interferon, a luteinizing hormone-releasing hormone (LHRH) analog, a somatostatin and / or derivatives thereof, a calicitonin, a parathyroid hormone (PTH), a bone morphogenic protein (BMP), an erythropoietin (EPO), an epidermal growth factor (EGF) or a growth hormone. This invention also relates to methods of using the composite microspheres, and methods of preparing same.

A compound is provided that has the formulaNH2CH2CH2CH2C(O)N—R  (I)where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidetransferrin, glucosylamnine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

A compound is provided that has the formulaNH2CH2CH2CHR1C(O)N—R   (I)where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosylamine, amino saccharin, lactylamine, leucine, tryptophan, glutamate and amino cholines.

The invention discloses a mountain area sturgeon parent breeding and artificial spawning method. The method comprises the steps that running water breeding is carried out on mountain area sturgeon parents, selection and male and female parent classification are carried out on the sturgeon parents two months before the breeding season, the selected male and female sturgeon parents are bred in different pools with controlled temperature, luteinizing hormone releasing hormone A3 is adopted as oxytocin to facilitate artificial spawning, and male sturgeon parents and female sturgeon parents are respectively and temporarily fed after spawning is finished. The mountain area sturgeon parent breeding and artificial spawning method is easy to operate and low in cost, the fertilization rate of sturgeon reaches 90.48%, 163.2 thousand sturgeon fry are hatched, the hatching rate is 66.55%, and the effect is quite obvious.

The invention belongs to the technical field of preparation of molecular markers for livestock, and particularly relates to a preparation method of a sheep lambing number trait related molecular marker serving as MAS (marker-assisted selection) as well as an application of the molecular marker. The molecular marker is obtained through LH (luteinizing hormone) beta gene cloning, and the nucleotide sequence is represented in SEQ ID NO.1. One C713-T713 base is substituted at 713 bp in the SEQ ID NO.1, so that BSrB I-RFLP (restricted fragment length polymorphisms) is caused. The invention further discloses a primer used in a DNA (deoxyribonucleic acid) sequence of an amplified LH beta gene part and a polymorphism detection method, and provides one novel molecular marker for MAS of the sheep lambing number trait.

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

A compound of the formulawhere R1 is H, C1–C4 alkyl and OH; R2 in is H, C1–C4 alkyl and OH; R3 is H and C1–C4 alkyl; R4 is H and C1–C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2–C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

An improvement to the method of intrauterine insemination by the administration of luteinizing hormone-releasing hormone antagonists (LHRH antagonists).

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

A compound of the formula where R1 is H, C1-C4 alkyl and OH; R2 in is H, C1-C4 alkyl and OH; R3 is H and C1-C4 alkyl; R4 is H and C1-C4 alkyl; n is an integer between 0 and 2 inclusive; R5 is a nullity, NHR7C(O)—, C6H4—, C6H4—O—; R7 is C2-C6 alkyl; and R6 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptidegluconate, transferrin, glucosylamine, amino saccharin, saccharin ester, lactylamine, leucine, tryptophan, amino glutamate and amino cholines.

The invention discloses a culturing method for sex reversal of a female carp to a male carp. The culturing method comprises the following steps that A. squeezing an abdomen of a 10-11-month-old carp, and separating a male carp with out-flown semen and a carp with no out-flown semen; B. inserting a copper roe digging device in a genital pore of the carp from which semen can not be squeezed, and selecting the carp capable of obtaining roe particles to cultivate the carp in a cement pond; C. according to the weight of the carp, feeding the carp with dosing fodders containing 17 alpha- methyltestosterone every day, and mix-injecting domperidone, luteinizing hormone releasing hormone and carp pituitary gland in the thoracic cavity of the carp in each five days; and D. after continuously processing the test carp for 2 months, squeezing the abdomen of the carp, the test carp with out-flown milky white semen is the sex reversal carp which is a female on genotype and a male on physiology. The culturing method is easy and feasible and is convenient in operation, and can be used for sex reversing the female carp on genotype into a male carp on physiology. The growth speed of the filial generation cross bred by the sex reversal carp and the common carp is fast and the economic benefits are remarkable.

The invention discloses a method for timely releasing panda pairs to allow natural mating. The method includes: accurately detecting LH (luteinizing hormone) peak and emergence time in female pandas according to true estradiol peak and emergency time thereof in female pandas; arranging normally ovulating female panda individuals for primary natural mating in 16-30 hours after the time of true estradiol peak according to such conditions as true estradiol peak, time intervals between LH peak and true estradiol peak, and whether the female pandas are in heat peak synchronously or not; arranging ovulation-delayed female panda individuals for primary natural mating in 16-30 hours after the time of true estradiol peak; and allowing for single or multiple times of natural mating. The period of primary natural mating is shortened from 48 hours to present 20 hours, success rate of natural mating in panda is increased from the traditional 21.05% to 46.15% finally, and the success rate is more than doubled.

This invention relates to a process for preparing a hapten-protein-polysaccharide conjugate and a hapten-protein conjugate by reacting a protein with a hapten to produce a hapten-protein conjugate, followed by reacting the hapten-protein conjugate with a polysaccharide to provide a conjugate mixture including the hapten-protein conjugate and a hapten-protein-polysaccharide conjugate. This invention also includes the process described above with the addition of a pharmaceutically acceptable medium or delivery vehicle into the conjugate mixture. The invention further includes the process described above where the hapten is luteinizing hormone releasing hormone peptides derived from E coil, or malaria derived peptides.

The invention provides an artificial breeding method of schizothorax waltoni. The artificial breeding method includes following steps: 1), domesticating wild schizothorax waltoni to obtain a reproduction parent fish; 2), injecting the reproduction parent fish with oxytocin composed of chorionic gonadotropin, luteinizing hormone-releasing hormone analogue and domperidone in two times for artificialspawning induction to obtain fertilized eggs; 3), adopting microflow water of 10-15 DEG C to artificially incubate the fertilized eggs to obtain schizothorax waltoni fries; 4), putting the schizothorax waltoni fries into a pond, and starting to feed food 10 days after the fries are hatched until the fries grow well to obtain schizothorax waltoni. Oxytocin is injected by means of injection in twotimes, injection dosage of each time is controlled strictly, well developed eggs and seminal fluid can be obtained, and fertilized egg incubating conditions are controlled, so that induced spawning rate of schizothorax waltoni is higher than 75%, fertilization rate is higher than 90%, hatching rate is higher than 85%, large-scale artificial breeding of schizothorax waltoni is realized, and the resource is protected effectively.

The invention relates to a luteinizing hormone nano-magnetic particle chemiluminescence assay kit and a preparation method thereof and an assay method thereof. The luteinizing hormone nano-magnetic particle chemiluminescence assay kit comprises a solution containing a fluorescein-labeled luteinizing hormone antibody, a suspension coated with magnetic particles of an anti-fluorescein antibody, and a solution containing an alkaline phosphatase-labeled luteinizing hormone antibody, wherein the alkaline phosphatase-labeled luteinizing hormone antibody is formed by connecting an alkaline phosphatase with a luteinizing hormone antibody through SMCC (4-(N-maleimidomethyl) cyclohexyl-1-succinimide carboxylate) and 2IT (2-imido sulfane hydrochloride). The luteinizing hormone nano-magnetic particle chemiluminescence assay kit can be used for quantitative determination of the luteinizing hormone at lower cost and higher accuracy and precision.

The invention discloses a magnetic particle Chemiluminescence Immunoassay determination kit of luteinizing hormone (LH), belonging to the field of immunoassay medical science. The kit comprises: 1) LH series of calibrators; (2) magnetic particle solution coated by monoclonal antibody resisting fluorescein isothiocyanate; (3) LH monoclonal antibody labeled by fluorescein isothiocyanate; (4) LH monoclonal antibody labeled by horse radish peroxidase; (5) chemiluminescence substrate liquid; and (6) washing concentrate. The invention also discloses a preparation method of the kit, and the kit has the advantages of simpleness, convenience, rapidness, sensitivity, stability, etc.

The invention discloses a luteinizing hormone nano-magnetic particle chemiluminescence quantitative immunoassay kit. The kit comprises a luteinizing hormone calibration product, a nano-magnetic particle suspension coupled with streptavidin, a biotin-marked luteinizing hormone antibody, a luteinizing hormone antibody enzyme binding substance, a luteinizing hormone quality control product, a chemiluminescence solution A and a chemiluminescence solution B, a 20-times concentrated washing solution and a reaction tube, wherein the used enzyme is horseradish peroxidase, the purity RZ of the horseradish peroxidase is not less than 3.0, and the activity is not less than 250U / mL. In addition, the invention further discloses a preparation method of the kit. Compared with the existing kit, the kit disclosed by the invention has the advantages of high sensitivity, a wide range of measurable concentrations, long effective period of a reagent, high degree of automation in detection and the like, and is simple to operate.

The invention discloses a method for artificially-induced spawning of little yellow croaker and belongs to the field of agricultural seawater fry rearing. The method includes that little yellow croaker of one year old and 100-200g in body weight is adopted as parent fishes for domestication strengthening; after strengthening, luteinizing hormone releasing hormone analogue number 2 (LHRH-A2) is adopted for dilution, the diluent is injected in one time, and the parent fishes can spawn in a cement pool after 24-26h. By the method, the little yellow croaker can smoothly spawn in the indoor cement pool, induced spawning rate can reach 75%, fertilized egg hatching rate reaches 80%, and needs on artificial fry cultivation of the little yellow croacker can be met.

The invention discloses a method for batch breeding of loach fry, which notably improves catalytic production rate of the loach. The method comprises the steps of: a, selecting loach parent for breeding to perform prenatal strengthening cultivation; b, building a third-level filtering reservoir device for spawning and hatching; c, selecting composite of the maleic acid domperidone and the trout luteinizing hormone releasing hormone analogue as a catalyst to catalyze male and female loaches, wherein per kilogram of female loaches need 10-15mg of the catalyst; per kilogram of male loaches need 5-7.5mg of the catalyst; enabling the female loaches and the male loaches to spawn and inseminate in a net cage in the jar according to the ratio of the female loaches to the male loaches being 1:2; taking out the loaches, enabling the spawns to continuously hatch; producing loach fry in a large scale; d, feeding the initial feed, putting the loaches to the pond; according to organ development characteristic of the loach fry, controlling diet conversion time point, electing palatable bait, scientifically feeding the bait, and strengthening water quality and disease control and prevention.

The invention provides a method for constructing a model of oriented differentiation of embryonic stem (ES) cells into testicular interstitial cells. The method comprises the following steps of: firstly, cotransfecting a steroidogenic factor 1 and a luteinizing hormone receptor plasmid into an ES cell; then inducing the ES cell by a compound or growth factor to directionally differentiate the ES cell into the testicular interstitial cell. In the invention, the construction and the application of the model for in-vitro oriented differentiation of the stem cells into the testicular interstitialcells are demonstrated at the cellular level; a great deal of biology information is discussed initially; the constructed cell model is a substituted model for researching the influencing factor of the secretory regulation function of the testicular interstitial cell and can be used for initially selecting and evaluating the medical effect of the pharmaceutical drug using the testicular interstitial cell as the target cells; the transplanting of the testicular interstitial cell differentiated from the stem cells is used as a new method for supplying testosterone, and the application prospect of the renewable alternative treatment of the testicular interstitial cell is improved.